Market Research Logo

Grunenthal GmbH - Product Pipeline Review - 2016

Grunenthal GmbH - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Grunenthal GmbH - Product Pipeline Review - 2016’, provides an overview of the Grunenthal GmbH’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Grunenthal GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Grunenthal GmbH
  • The report provides overview of Grunenthal GmbH including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Grunenthal GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Grunenthal GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Grunenthal GmbH’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Grunenthal GmbH
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Grunenthal GmbH’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Grunenthal GmbH Snapshot
Grunenthal GmbH Overview
Key Information
Key Facts
Grunenthal GmbH - Research and Development Overview
Key Therapeutic Areas
Grunenthal GmbH - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Grunenthal GmbH - Pipeline Products Glance
Grunenthal GmbH - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Grunenthal GmbH - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Grunenthal GmbH - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Grunenthal GmbH - Unknown Stage Pipeline Products
Unknown Products/Combination Treatment Modalities
Grunenthal GmbH - Drug Profiles
cebranopadol
Product Description
Mechanism of Action
R&D Progress
tapentadol hydrochloride
Product Description
Mechanism of Action
R&D Progress
Small Molecule 1 for Pain
Product Description
Mechanism of Action
R&D Progress
Small Molecule 2 for Pain
Product Description
Mechanism of Action
R&D Progress
GRTTA-2210
Product Description
Mechanism of Action
R&D Progress
RO-656570
Product Description
Mechanism of Action
R&D Progress
Small Molecule 3 for Pain
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate KCNQ and TSPO for Pain
Product Description
Mechanism of Action
R&D Progress
Grunenthal GmbH - Pipeline Analysis
Grunenthal GmbH - Pipeline Products by Target
Grunenthal GmbH - Pipeline Products by Route of Administration
Grunenthal GmbH - Pipeline Products by Molecule Type
Grunenthal GmbH - Pipeline Products by Mechanism of Action
Grunenthal GmbH - Recent Pipeline Updates
Grunenthal GmbH - Dormant Projects
Grunenthal GmbH - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
axomadol
lexanopadol
Grunenthal GmbH - Company Statement
Grunenthal GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Grunenthal GmbH, Key Information
Grunenthal GmbH, Key Facts
Grunenthal GmbH - Pipeline by Indication, 2016
Grunenthal GmbH - Pipeline by Stage of Development, 2016
Grunenthal GmbH - Monotherapy Products in Pipeline, 2016
Grunenthal GmbH - Partnered Products in Pipeline, 2016
Grunenthal GmbH - Partnered Products/ Combination Treatment Modalities, 2016
Grunenthal GmbH - Phase III, 2016
Grunenthal GmbH - Phase II, 2016
Grunenthal GmbH - Phase I, 2016
Grunenthal GmbH - Preclinical, 2016
Grunenthal GmbH - Discovery, 2016
Grunenthal GmbH - Unknown, 2016
Grunenthal GmbH - Pipeline by Target, 2016
Grunenthal GmbH - Pipeline by Route of Administration, 2016
Grunenthal GmbH - Pipeline by Molecule Type, 2016
Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2016
Grunenthal GmbH - Recent Pipeline Updates, 2016
Grunenthal GmbH - Dormant Developmental Projects,2016
Grunenthal GmbH - Discontinued Pipeline Products, 2016
Grunenthal GmbH, Other Locations
Grunenthal GmbH, Subsidiaries
List of Figures
Grunenthal GmbH - Pipeline by Top 10 Indication, 2016
Grunenthal GmbH - Pipeline by Stage of Development, 2016
Grunenthal GmbH - Monotherapy Products in Pipeline, 2016
Grunenthal GmbH - Partnered Products in Pipeline, 2016
Grunenthal GmbH - Pipeline by Target, 2016
Grunenthal GmbH - Pipeline by Route of Administration, 2016
Grunenthal GmbH - Pipeline by Molecule Type, 2016
Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report